Details of the Drug Formulations

General Information of Drug (ID: DM958QB)

• Drug Name: Ripretinib Drug Info
• Synonyms: 1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal stromal tumour	2B5B	Approved	[1]
Glioma	2A00.0	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
Systemic mastocytosis	2A21.0	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 71584930
  CAS Number: 1442472-39-0
  TTD ID: D09AAK
  ACDINA ID: D01395

Full List of Drug Formulations Containing This Drug

Ripretinib 50 mg tablet

Company	Formulation ID	FDA Description
Deciphera Pharmaceuticals	F23277	Crospovidone; Hypromellose Acetate Succinate; Lactose Monohydrate; Magnesium Stearate; Microcrystalline Cellulose; Silicon Dioxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)